论文部分内容阅读
目的观察艾普拉唑治疗糜烂性反流性食管炎的疗效和安全性。方法 29例糜烂性反流性食管炎患者予艾普拉唑10mg/d口服(20例,A组)和埃索美拉唑40mg/d口服(9例,B组),比较两组患者内镜下食管黏膜愈合情况、临床症状改善及不良事件发生情况。结果两组治疗4周和8周内镜下食管黏膜治愈例数相仿(P>0.05)。两组治疗后临床症状程度积分均低于治疗前(P<0.05)。A组治疗8周临床症状改善率高于B组[(86.81±24.69)%vs.(78.24±34.47)%](P<0.05)。用药期间两组均无一例严重不良事件发生。结论艾普拉唑对糜烂性反流性食管炎的治疗效果与埃索美拉唑相当,且起效快、安全性好,值得临床推广。
Objective To observe the efficacy and safety of ilaprazole in the treatment of erosive reflux esophagitis. Methods Twenty-nine patients with erosive esophagitis were treated orally with 10 mg / d of ioprazole orally (n = 20, group A) and 40 mg / d of esomeprazole (n = 9) Microscopic esophageal mucosal healing, clinical symptoms and adverse events. Results The cure rate of esophageal mucosa in the two groups was similar at 4 weeks and 8 weeks (P> 0.05). After treatment, the scores of clinical symptoms were lower than before treatment (P <0.05). The improvement rate of clinical symptoms in group A at 8 weeks was higher than that in group B [(86.81 ± 24.69)% vs (78.24 ± 34.47)%] (P <0.05). No serious adverse events occurred in both groups during the treatment. Conclusions Ilaprazole is equivalent to esomeprazole in the treatment of esophageal reflux esophagitis and has rapid onset and good safety. It is worthy of clinical promotion.